SAN FRANCISCO, April 10, 2017 -- Today Zephyr Health, the leading Insights-as-a-Service company, released a report entitled “Powering the Life Sciences Commercial Engine with Market Access Insights.” Based on results from a survey of 60 industry leaders working in market access, medical affairs, marketing and sales, the report examines the challenges with effective market access data integration between market access and commercial teams, and key opportunities to reengineer the business for the future.
According to this report, all survey respondents recognized the importance of a market access-driven commercial model, and the need to more effectively share data to gain any competitive advantage that a formulary change might offer. In fact, more than 40% of participants cite data integration and sharing as the biggest barrier to collaboration between managed markets and sales and marketing teams. Organizational silos and disparate technology solutions play a significant role in these challenges.
“It’s clear from the survey that the Life Sciences industry still needs solutions for effective pull-through by field sales for market access opportunities created by managed care teams” said Lance Scott, chief executive officer, Zephyr Health. “While pharmaceutical companies have a clear understanding of the power these insights can provide, in terms of commercial success, breaking down silos throughout the organization is essential to data integration of any kind. However, these efforts must be supplemented with technology that disseminates rich and predictive insights across the organization in order to stay ahead of competition.”
The “Powering the Life Sciences Commercial Engine with Market Access Insight” global survey examined the landscape for pharmaceutical companies seeking to bridge the insights gap between market access teams and other commercial functions. For more information, download a copy of the Zephyr Health report.
About Zephyr Health
Zephyr Health helps Life Sciences companies – pharmaceutical, biotech, medical device and diagnostics – engage the right physicians, accounts and institutions using insights from global health data. Zephyr Illuminate™ is a leading Insights-as-a-Service solution that integrates thousands of data sources to create precise and predictive insights. From pre-launch to product maturity, Life Sciences companies can make confident decisions faster with data-driven targeting and deep customer profiles.
Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK, and Pune, India. Zephyr Health is venture backed by Google Ventures, Kleiner Perkins Caufield & Byers, and Icon Ventures. For more information, please visit: www.zephyrhealth.com.
Media contact for Zephyr Health: [email protected]


Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 



